CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. W...
Phase 3
Valencia, Spain and 32 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Valencia, Spain and 321 other locations
compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...
Phase 2
Valencia, Spain and 94 other locations
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...
Phase 3
Valencia, Spain and 312 other locations
This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...
Phase 2
Valencia, Spain and 100 other locations
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...
Phase 3
Valencia, Spain and 173 other locations
receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...
Phase 2
Valencia, Spain and 210 other locations
function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The st...
Phase 2
Valencia, Valenciana, Comunitat, Spain and 30 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Valencia, Spain and 943 other locations
International, multicentre, randomized 1:1 controlled trial to prove the clinical and medico economic benefits of the medical device Predigraft, by s...
Valencia, Spain and 15 other locations
Clinical trials
Research sites
Resources
Legal